Advanced glycation end products are associated with arterial stiffness in type 1 diabetes

Journal of Endocrinology

Volumn 221, Issue 3, 2014, Pages 405-413

  Llauradó, Gemma ^a,d   Ceperuelo Mallafré, Victòria ^b   Vilardell, Carme ^c   Simó, Rafael ^a   Gil, Pilar ^d   Cano, Albert ^a   Vendrell, Joan ^d   González Clemente, José Miguel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c Althaia   (Spain)

^d HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Advanced glycation end products; Arterial stiffness; Arteriosclerosis; Pulse wave velocity; Skin autofluorescence; Type 1 diabetes mellitus

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; AUTOFLUORESCENCE IMAGING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULSE WAVE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TONOMETRY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADVANCED GLYCATION END PRODUCTS; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; PULSE WAVE VELOCITY; SKIN AUTOFLUORESCENCE; TYPE 1 DIABETES MELLITUS;

ADULT; AORTA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LINEAR MODELS; LYSINE; MALE; MIDDLE AGED; OPTICAL IMAGING; PULSE WAVE ANALYSIS; SKIN; SPECTROMETRY, FLUORESCENCE; VASCULAR STIFFNESS;

EID: 84901602307     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0407     Document Type: Article

References (29)

1. Cavalcante JL, Lima JA, Redheuil A & Al-Mallah MH 2011 Aortic stiffness: current understanding and future directions. Journal of the American College of Cardiology 57 1511-1522. (doi:10.1016/j.jacc.2010.12.017)
2. Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS & Baik SH 2009 Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. International Journal of Cardiology 132 96-101. (doi:10.1016/j.ijcard.2007.10.047)
3. Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE & Orchard TJ 2012 Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care 35 2331-2336. (doi:10.2337/dc12-0053)
4. Genevieve M, Vivot A, Gonzalez C, Raffaitin C, Barberger-Gateau P, Gin H & Rigalleau V 2013 Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. Diabetes & Metabolism 39 349-354. (doi:10.1016/j.diabet.2013.03.003)
5. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W & Monnier VM 2005 Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54 3103-3111. (doi:10.2337/diabetes.54.11.3103)
6. Goldin A, Beckman JA, Schmidt AM & Creager MA 2006 Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 597-605. (doi:10.1161/CIRCULATION AHA.106.621854)
7. Hallal PC & Victora CG 2004 Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Medicine and Science in Sports and Exercise 36 556. (doi:10.1249/01.MSS.0000117161.66394.07)
8. Januszewski AS, Sachithanandan N, Karschimkus C, O'Neal DN, Yeung CK, Alkatib N & Jenkins AJ 2012 Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabetic Medicine 29 726-733. (doi:10.1111/j.1464-5491.2011.03562.x)
9. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC & Lakatta EG 2001 Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 1464-1470. (doi:10.1161/hc3801.097806)
10. Komosinska-Vassev K, Olczyk P, Winsz-Szczotka K, Klimek K & Olczyk K 2012 Plasma biomarkers of oxidative and AGE-mediated damage of proteins and glycosaminoglycans during healthy ageing: a possible association with ECM metabolism. Mechanisms of Ageing and Development 133 538-548. (doi:10.1016/j.mad.2012.07.001)
11. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I & Struijker-Boudier H 2006 Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal 27 2588-2605. (doi:10.1093/eurheartj/ehl254)
12. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ et al. 2005 Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111 3489-3493. (doi:10.1161/CIRCULATIONAHA.104.529651)
13. Llaurado G, Ceperuelo-Mallafre V, Vilardell C, Simo R, Freixenet N, Vendrell J & Gonzalez-Clemente JM 2012 Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: a potential role of low-grade inflammation. Diabetes Care 35 1083-1089. (doi:10.2337/dc11-1475)
14. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ & Smit AJ 2009 Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52 789-797. (doi:10.1007/s00125-009-1308-9)
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S et al. 2007 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 28 1462-1536. (doi:10.1093/eurheartj/ehm236)
16. McNulty M, Mahmud A & Feely J 2007 Advanced glycation end-products and arterial stiffness in hypertension. American Journal of Hypertension 20 242-247. (doi:10.1016/j.amjhyper.2006.08.009)
17. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO & Smit AJ 2004 Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47 1324-1330. (doi:10.1007/s00125-004-1451-2)
18. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO & Smit AJ 2007 Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30 107-112. (doi:10.2337/dc06-1391)
19. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2002 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 3143-3421.
20. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P & Stehouwer CD 2011 Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 34 442-447. (doi:10.2337/dc10-1087)
21. Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N & Stehouwer CD 2005 Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 46 232-237. (doi:10.1161/01.HYP. 0000164574.60279.ba)
22. Sell DR & Monnier VM 2012 Molecular basis of arterial stiffening: role of glycation. Gerontology 58 227-237. (doi:10.1159/000334668)
23. Semba RD, Najjar SS, Sun K, Lakatta EG & Ferrucci L 2009 Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. American Journal of Hypertension 22 74-79. (doi:10.1038/ajh. 2008.320)
24. Singh R, Barden A, Mori T & Beilin L 2001 Advanced glycation end-products: a review. Diabetologia 44 129-146. (doi:10.1007/s001250051591)
25. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, TaharaH, KakiyaR, Tabata T et al. 2008 Skin autofluorescence, amarker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism: Clinical and Experimental 57 1452-1457. (doi:10.1016/j.metabol.2008.05.016)
26. Vlachopoulos C, Aznaouridis K & Stefanadis C 2010 Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American College of Cardiology 55 1318-1327. (doi:10.1016/j.jacc.2009.10.061)
27. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M & Wautier JL 2003 N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2'diabetic patients. Diabetes & Metabolism 29 44-52. (doi:10.1016/S1262-3636(07)70006-X)
28. Zieman SJ & Kass DA 2004 Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64 459-470. (doi:10.2165/00003495-200464050-00001)
29. Zieman SJ, Melenovsky V & Kass DA 2005 Mechanisms, pathophysiology, and therapy of arterial stiffness. Arteriosclerosis, Thrombosis, and Vascular Biology 25 932-943. (doi:10.1161/01.ATV.0000160548.78317.29)